<DOC>
	<DOCNO>NCT02551432</DOCNO>
	<brief_summary>Patients refractory SCLC . Patients treat paclitaxel pembrolizumab .</brief_summary>
	<brief_title>Pembrolizumab Paclitaxel Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>Open , uncontrolled , multi-center , phase II study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Be willing able provide write informed consent/assent trial . 2 . Be 20 year age day sign informed consent . 3 . Have measurable lesion base RECIST 1.1 . 4 . Have provide tissue archival tissue sample obtain last previous treatment newly obtain core excisional biopsy tumor lesion . 5 . Have performance status 0 1 ECOG Performance Scale . 6 . Demonstrate adequate organ function define 'adequate organ fuction laboratory value ' , screen lab perform within 10 day treatment initiation . 'adequate organ fuction laboratory value ' System Laboratory Value Hematological Absolute neutrophil count ( ANC ) ≥ 1,500 /mcL Platelets ≥100,000 / mcL Hemoglobin ≥ 9 g/dL ≥ 5.6 mmol/L Renal Serum creatinine OR Measured calculateda creatinine clearance ( GFR also use place creatinine CrCl ) ≤1.5 X upper limit normal ( ULN ) OR ≥ 60 mL/min subject creatinine level &gt; 1.5 X institutional ULN Hepatic Serum total bilirubin≤ 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN OR 5 X ULN subject liver metastasis Coagulation International Normalized Ratio ( INR ) Prothrombin Time ( PT ) 1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant Activated Partial Thromboplastin Time ( aPTT ) ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant aCreatinine clearance calculate per institutional standard . 7 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 8 . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication ( Reference Section 5.7.2 ) . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . 9 . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . 1 . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has prior anticancer monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 4 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 5 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . 6 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . 7 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 8 . Has evidence interstitial lung disease active , noninfectious pneumonitis . 9 . Has active infection require systemic therapy . 10 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 11 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 12 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 13 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . 14 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 15 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . ( inactive HBsAg carrier prophylactic antiviral agent allow ) 16 . Has receive live vaccine within 30 day prior first dose trial treatment . 17 . Has know history active TB ( Bacillus Tuberculosis ) 18 . Has know hypersensitivity MK3475 excipients</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pembrolizumab</keyword>
	<keyword>paclitaxel</keyword>
</DOC>